Detection of microRNA‑33a‑5p in serum, urine and renal tissue of patients with IgA nephropathy
- Authors:
- Published online on: January 11, 2021 https://doi.org/10.3892/etm.2021.9638
- Article Number: 205
-
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The present study aimed to detect the levels of microRNA (miR)‑33a‑5p in the renal tissue, serum and urine of patients with primary IgA nephropathy (IgAN), thereby preliminarily exploring the association between the levels of miR‑33a‑5p and the condition of primary IgAN to provide evidence for the expression of miR‑33a‑5p in the serum and urine of IgAN patients as a clinical marker. Reverse‑transcription quantitative PCR was performed to evaluate the level of miR‑33a‑5p in IgAN patients according to severity and pathological classification. The results suggested that the levels of miR‑33a‑5p in the serum, urine and kidney tissues of patients with IgAN were lower than those of the control tissues obtained from cancer patients (0.28±0.25 vs. 1.00±0.45, P<0.05; 0.34±0.28 vs. 1.00±0.53, P<0.05; 0.47±0.27 vs. 1.00±0.38, P<0.05, respectively). Receiver operating characteristic curve analysis suggested that the serum and urine levels of miR‑33a‑5p may be used as a marker to differentiate renal injury in IgAN patients from healthy individuals. At the same time, according to the estimated glomerular filtration rate (eGFR) and Lee classification of nephropathy, it was determined that with the progression of renal failure and the increase of the pathological grade of kidney tissue, the relative level of miR‑33a‑5p in kidney tissue also decreased (eGFR <50 ml/min vs. eGFR ≥50 ml/min/1.73 m2 group: 0.38±0.27 vs. 1.00±0.34, P<0.001; Lee grade ≤3 group vs. Lee grade >3: 1.00±0.48 vs. 0.38±0.45, P<0.05). This result suggested that the levels of miR‑33a‑5p in serum, urine and kidney tissues decreased with the severity of renal injury and the progression of renal failure in patients with IgAN. Hence, miR‑33a‑5p detected in the serum and urine may be used as a non‑invasive biomarker to reflect the progression of renal injury and renal failure in patients with IgAN.
